We selected the 6-month post-treatment AFP level > 5.0 ng/mL (75 percentile of AFP level) and platelet level < 130 ×1000/μL (25 percentile of platelet level) as the parameters to predict HCC development Patients with both parameters had higher risk of HCC development, compared with patients who had neither of the parameters (HR: 15.96, 95% CI 4.135– 1.598, P < 0.001) (Table 4). This evidence concerns the gene AFP and hepatocellular carcinoma.